Evidence map›Paper›PMID 36844639›Full record

ArticleSaudi journal of biological sciences2023

The impact of

Faisal M Alzahrani, Jinan A Alhassan, Abdullah M Alshehri, Faraz A Farooqi, Maryam A Aldossary, Magdy K Abdelghany, Hafiz Ibrahim, Omar S El-Masry

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Saudi journal of biological sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Reduced abundance ofFrontiers in pharmacology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Faisal M AlzahraniDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, Imam Abdulrahman Bin Faisal University. P.O.Box 1982, Dammam 31441, Saudi Arabia.
Jinan A AlhassanDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, Imam Abdulrahman Bin Faisal University. P.O.Box 1982, Dammam 31441, Saudi Arabia.
Abdullah M AlshehriDepartment of Medicine, College of Medicine, Imam Abdulrahman Bin Faisal University, P.O.Box 1982, Dammam 31441, Saudi Arabia.
Faraz A FarooqiCollege of dentistry, Imam Abdulrahman Bin Faisal University, P.O.Box 1982, Dammam 31441, Saudi Arabia.
Maryam A AldossaryDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, Imam Abdulrahman Bin Faisal University. P.O.Box 1982, Dammam 31441, Saudi Arabia.
Magdy K AbdelghanyDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, Imam Abdulrahman Bin Faisal University. P.O.Box 1982, Dammam 31441, Saudi Arabia.
Hafiz IbrahimDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, Imam Abdulrahman Bin Faisal University. P.O.Box 1982, Dammam 31441, Saudi Arabia.
Omar S El-MasryDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, Imam Abdulrahman Bin Faisal University. P.O.Box 1982, Dammam 31441, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cardiovascular diseases (CVD) are leading cause of mortality in patients with type 2 diabetes mellitus (T2DM). Increased soluble sP-selectin and 715Thr > Pro polymorphism were studied in CVD and T2DM, but association between them hasn't been explored in Saudi Arabia. We aimed to assess sP-selectin levels in T2DM and T2DM-associated CVD patients in comparison to healthy control cohort. Also, we sought to investigate relationship between Thr715Pro polymorphism and sP-selectin levels and disease state. Methods: This is a cross-sectional case-control study. sP-selectin level (measured by Enzyme-linked immunosorbent assay) and prevalence of Thr715Pro polymorphism (assessed by Sanger sequencing) were investigated in 136 Saudi participants. The study comprised 3 groups: group1 included 41 T2DM patients; group 2 (48 T2DM patients with CVD), and group 3 (47 healthy controls). Results: sP-selectin levels were significantly higher in diabetics and diabetics + CVD groups as compared to the corresponding control. In addition, results showed that the prevalence of 715Thr > Pro polymorphism is 11.75 % in the study population amongst the three study groups (9.55 % Conclusion: Our study supports the previous researches' results that Thr715Pro is neither influencing the sP-selectin level nor the risk of CVD in T2DM patients.

Indexed as

ACE-I, Angiotensin-converting enzyme inhibitorsARB, Angiotensin II receptor blockersBMI, Body-mass indexCAM, Cell adhesion moleculeCardiovascular diseaseCCB, Calcium channel blockersCVD, Cardiovascular diseaseDM, Diabetes mellitusELISA, Enzyme-linked immunosorbent assayGp1bα, Platelet glycoprotein 1b-alphaIDF, International Diabetes FederationIR, Insulin resistancePMN, Polymorphonuclear leukocytespP-selectin, Platelet P-selectinPSGL-1, P-selectin glycoprotein ligand-1SELP, P-selectin genesP-selectinsP-selectin, Soluble P-selectinT2DM, Type 2 diabetes mellitusThr715Pro polymorphismType 2 diabetesvWF, Von-Willebrand factorWPb, Weibel-Palade Bodies

Identifiers

PMID36844639
PMCPMC9944555

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.